Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Fondazione Italiana Linfomi - ETS
With
Istituto Clinico Humanitas
This is a prospective observational study in which patients with positive PET scan after salvage therapy are candidates to a sequential scheme "auto-allotransplantation" in case of availability of a donor . In the event of unavailability of a donor , the same patients are candidates for a double high-dose chemotherapy with autologous stem cell support.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients confirmed Hodgkin's lymphoma at refractory at first line therapy, relapse early or late;
Age \> 18 years;
Life expectancy \> 3 months;
Cardiac, pulmonary, renal and liver functions with normal range;
Written informed consent.
You may not be if
Any psychological, familiar or geographical conditions that could potentially hinder the compliance to the protocol;
renal failure as creatinine\> 1.2 mg/dl or creatinine clearance \<60 ml/min;
AST/ALT or bilirubin\> 2.5 times the norm;
HCV positivity with signs of ongoing viral replication (HCV PCR + AST\>1.5-2x normal);
Heart disease clinically significant: eg. severe hypertension not controlled, multifocal uncontrolled cardiac arrhythmias, symptomatic ischemic heart disease or congestive heart failure class NYHA class III-IV (Annex 2), previous acute myocardial infarction;
Ventricular ejection fraction \<45%;
decompensated diabetes mellitus not controlled by insulin therapy; Disease with significant pulmonary function defined as FEV1 \<65% of predicted or DLCO \<50% of predicted value;
HIV positive patients;
Patients with uncontrolled infection;
Neoplasia in the last 3 years except carcinoma in situ uterus, neck and basal skin cancer or prostate cancer in early stage localized exeresi treated with surgery or brachytherapy with curative intent, a good prognosis DCIS breast treated with surgery alone;
Drug addiction or alcoholism.
Clareo Health | Consolidation PET-based and Donor-based After Salvage Therapy in Patients With HL in Relapse or Refractory
